Lazard Inc (NYSE: LAZ) — A Turnaround Without a Moat, Priced for No Recovery

Report date: 2026-07-19 | Independent equity research note | Fresh initiation — no prior LAZ report

⚡ Kimi’s Take

Kimi’s own subjective opinion and independent view; for general information only, not investment advice. The analytical body below carries no position.

HOLD / small accumulate on weakness toward $35–38. Lazard is a cyclical advisory franchise with a mediocre asset manager attached, undergoing a management, AI, and productivity turnaround under Peter Orszag. At ~$43 the stock trades at ~16.6x trailing earnings and a ~4.6% dividend yield. That multiple is fair for a mid-cycle outcome, not cheap for a trough, and not demanding for a recovery. The position is therefore not a strong buy — there is no durable moat, SBC-driven dilution is reversing the share count, and Asset Management only recently posted its first quarterly inflow after five years of outflows. It is also not a short: the balance sheet is safe (net debt/EBITDA ~0.5x), the dividend is covered by normalized free cash flow, and Campbell Lutyens adds a real, if unproven, call option on private-capital advisory revenue.

Framing: contrarian turnaround / cyclical recovery, with a falling-knife watch. The factor tape shows LAZ as a high-beta dividend/financial/broker-dealer bundle, currently below its 50- and 200-day EMAs and ~24% off the 52-week high. The 1-year broker-dealer factor regime has been a headwind, while the dividend-yield factor has provided a floor. Momentum is absent and Quality is not a differentiator, so the stock is unlikely to work until capital-markets optimism or value/financials leadership returns.

Conviction: Medium-low. Bull-flip trigger: two consecutive quarters of advisory revenue growth re-accelerating above +10% YoY and AM net inflows sustained above $5B/quarter, which would validate the Lazard 2030 inflection. Bear-flip trigger: Q2/Q3 2026 advisory revenue falls back toward a $1.4B annualized run rate while the adjusted comp ratio stays stuck above 65%, squeezing operating leverage and putting the $2.00 annual dividend under scrutiny.

Tag: A people business with a plan, priced as if the plan doesn’t matter.

📈 Stock Price Action — Five-Year Event Map

Lazard’s trailing five years trace a deep capital-markets cycle: a 5-year low of $23.73 on November 13, 2023, a 5-year high of $56.90 on November 6, 2024, and a current price of $43.16 as of July 17, 2026 — ~24% below the 52-week high of $56.41 and ~82% above the 5-year low. The 52-week range is $38.70 (March 27, 2026) to $56.41 (February 9, 2026).

The arc is straightforward. The June 2022 trough was the first repricing of a higher-rate world in which M&A multiples and deal flow collapsed; Lazard fell with the capital-markets complex. The November 2022 CPI-driven bounce showed the stock’s high beta (~1.6) in a risk-on macro rotation. The November 2023 low combined a year of restructuring charges, weak advisory revenue, and the transition to Peter Orszag as CEO. The July 2024 surge mixed a large one-time real-estate gain with a recovering advisory narrative. The November 2024 peak captured post-election financial-beta euphoria and M&A-cycle optimism. The April 2025 tariff crash and violent bounce were exogenous; Q1 2025 earnings landed after the dust settled. The April 2026 bounce reflected the Edgewater gain and the Campbell Lutyens acquisition, while the June 2026 selloff was a macro/geopolitical de-risking in high-beta financials with no LAZ-specific catalyst.

1. Executive Summary

Lazard Inc is a 178-year-old independent financial-advisory and asset-management firm. Financial Advisory generated ~59% of FY2025 net revenue ($1,834M of $3,099M) and Asset Management generated ~41% ($1,275M). The advisory business is a capital-light, cyclical, success-fee operation with no long-term contracted revenue, high dependence on Managing Director talent, and genuine but narrow brand strength in cross-border, sovereign, and restructuring mandates. The asset-management business is a mediocre AUM-gatherer: five consecutive years of net outflows (2020–2025), a sub-50 bps fee rate, and no scale moat against BlackRock/Vanguard or alternatives brand against Blackstone/Apollo.

The investment case rests on the “Lazard 2030” plan introduced by CEO Peter Orszag in September 2023: double firmwide revenue from ~$2.5B in 2023 to ~$5B by 2030, raise revenue per Managing Director from ~$8.7M to $12.5M, shift private-capital-connected advisory revenue to ~50% of the advisory total, and use AI to improve research and eventually shrink support staff. The April 2026 all-stock acquisition of Campbell Lutyens — a fund-placement, secondaries, and GP-capital advisory business — is the signature strategic move: up to $660M of total consideration ($460M upfront + $115M deferred + up to $85M earn-out), a $46.50 reference share price, and an expected ~$500M of combined 2027 revenue at mid-20s operating margins.

Financial quality is mixed. Revenue and margins are highly cyclical: operating margin peaked at 24.4% in 2021, troughed at -1.7% in 2023, and was 12.0% in FY2025 (14.3% adjusted). The adjusted compensation ratio is sticky around 65–66% of revenue, leaving limited operating leverage for shareholders. Balance-sheet risk is low — net debt/EBITDA ~0.5x, long-dated senior notes, no near-term maturities — but earnings quality is clouded by recurring “special” charges (management transitions, real-estate gains/losses, LFI-related items). Free cash flow is healthy outside restructuring years ($487M in 2025) and the dividend is covered, though share count has risen from 86.0M at YE2022 to 99.5M at Q1 2026 as SBC issuance outpaces buybacks.

At ~$43, LAZ trades at ~16.6x trailing P/E, ~5.2x P/B on diluted/common equity, ~1.4x P/S, and a ~4.6% dividend yield. That is a mid-cycle multiple: cheaper than pure boutiques (Evercore ~22x, Houlihan Lokey ~23x, PJT ~24x) but in line with bulge brackets (MS ~17x, GS ~17x, JPM ~16x). The market is underwriting a no-melt-down advisory outcome, stable asset-management revenue, and modest Campbell Lutyens contribution. The bull case — Campbell Lutyens accretion, a restructuring upswing, and sustained AM inflows — is only partially priced. The bear case — advisory-cycle rollover, stalled margin expansion, and continued share-count dilution — is also only partially priced.

The central debate for investors is whether Lazard 2030 is a credible strategic inflection or a consulting slide deck wrapped around a cyclical recovery. The evidence is genuinely ambiguous. The plan has concrete metrics, a new CEO with a public-sector and macro advisory background, a large all-stock acquisition that advances the private-capital revenue mix, and early signs of AM stabilization. Against that, the compensation ratio is not improving toward the 60% target, advisory growth is trailing faster peers, AM outflows persisted for five years, and the share count is expanding again. The stock’s factor profile — high beta to financials and broker-dealers, positive dividend-yield loading, no momentum, no quality premium — suggests the tape is treating LAZ as a cyclical value expression rather than a compounding growth story.

Verdict: Lazard is a fair-priced cyclical with optionality, not a high-conviction compounder. The advisory franchise is real but structurally weaker than Evercore’s platform and less cycle-hedged than Houlihan Lokey’s. Asset Management remains a headwind. The turnaround is plausible but unproven, and the stock’s factor profile offers no momentum tailwind.

2. Business Overview

2.1 What Lazard does

Lazard operates two reportable segments.

Financial Advisory (FA) provides M&A advisory, strategic capital solutions, shareholder advisory, sovereign and geopolitical advisory, restructuring and liability management, capital raising and placement, and private capital advisory. Revenue is almost entirely fee-based and success-driven. M&A and capital-raising engagements typically pay a success fee tied to transaction value, often with a modest retainer. Restructuring and liability-management engagements may pay monthly retainers plus a success fee upon emergence or refinancing. Sovereign and shareholder advisory work is more retainer-based but still episodic and lumpy. There are no long-term contracted sources of revenue; each engagement is separately negotiated and awarded. Top-10 clients accounted for ~17% of FA net revenue in FY2025, with no single client above 10% (LAZ 10-K FY2025, Item 1 and Risk Factors). At year-end 2025 Lazard had 216 FA Managing Directors.

The episodic nature of advisory revenue creates both operating leverage and volatility. In strong M&A markets, incremental revenue drops through with limited marginal cost, lifting margins toward the mid-20% range. In weak markets, compensation and occupancy costs are sticky, so margins can compress sharply or turn negative, as they did in FY2023. Q1 is seasonally the weakest advisory quarter; Q1 2026 adjusted FA operating margin was 9.8% versus 24.1% for the full year FY2025.

Asset Management (AM) offers active equity, fixed income, multi-asset, alternative investments, private equity funds, and cash-management strategies. AUM was $254.3B at December 31, 2025, up 12% YoY but still below the $273.7B peak at year-end 2021. The client base is ~82% institutional/intermediary and ~18% individual; ~67% of AUM has foreign-currency exposure; and top-10 clients represent 24% of AUM (LAZ 10-K FY2025, MD&A). At year-end 2025 Lazard had 124 AM Managing Directors. Revenue is primarily management fees calculated as a percentage of average AUM, plus performance and incentive fees that are lumpier. The blended fee rate has ranged between 49 and 53 bps annually, low by active-equity standards and reflecting the institutional, index-aware, and fixed-income tilt of the book.

Corporate/Other includes net revenue from principal investing (Lazard Financial Insurance and related vehicles), treasury, and corporate activities. FY2024 included a $114.3M gain on the sale of an owned office building; excluding that, Corporate revenue would have been roughly breakeven. This segment is a residual and should not be treated as a recurring profit pool.

2.2 Revenue split and trajectory

Sources: LAZ 10-K FY2023 segment table; LAZ 10-K FY2025 Note 23; source correction — FY2025 net revenue is $3,098.8M, not $3,148M or $3.15B.

The revenue arc is the advisory cycle in miniature: peak in 2021, 22% collapse in advisory revenue by 2023, and a partial recovery by 2025. Asset Management revenue has been more stable but trendless, failing to make a new high even as equity markets rallied. The Corporate/Other line is noisy due to real-estate gains and losses.

2.3 Adjusted segment margins

Management reports adjusted segment operating income, which excludes special charges such as cost-saving initiatives, management transitions, real-estate gains, and LFI-related items.

Source: LAZ 10-K FY2025 MD&A segment tables.

Advisory margins collapsed in 2023 when revenue fell faster than cost cuts, then rebounded to 24.2% in 2025 as deal activity recovered. AM margins are healthier but compressed by fee pressure and outflows. The key takeaway: advisory is the dominant profit engine and the dominant source of volatility.

2.4 Geographic and client footprint

Financial Advisory revenue in FY2025 was Americas 60%, EMEA 39%, Asia-Pacific 1%. Asset Management revenue was Americas 44%, EMEA 42%, Asia-Pacific 14% (LAZ 10-K FY2025 MD&A). The firm is therefore far more internationally balanced than a typical U.S. boutique, with EMEA exposure that adds both diversification and geopolitical/currency risk.

Verdict: Lazard is a cyclical advisory franchise with a stabilizing but structurally challenged asset manager attached. The revenue mix is reasonably diversified by geography, but the business model is concentrated in non-recurring, people-dependent advisory fees.

3. Industry Dynamics

3.1 The independent advisory cohort

Lazard sits in an elite independent-advisory cohort alongside Evercore, PJT, Moelis, Houlihan Lokey, and the private Centerview Partners. This cohort has gained significant share from bulge-bracket banks over the past decade: under 15% of U.S. M&A advisory fees in 2018 and more than 27% by 2024, per Dealogic/WSJ compilations replicated by CT Acquisitions. The drivers are independence/conflict-free advice, senior-level attention, and the ability to pay star bankers more than bulge brackets at the margin.

The profit pool is large but cyclical. Global M&A advisory fees are typically estimated at $80–120B annually depending on deal volume, with restructuring, shareholder activism, and sovereign advisory adding a further $10–15B. The independent boutiques capture the high-end, conflict-driven portion of this pool — special committees, cross-border deals, sponsor-driven transactions, and distressed situations where a bulge bracket’s balance sheet or lending relationships create conflicts. Lazard’s heritage in cross-border and sovereign advisory (it advised the Greek government during the eurozone crisis and has a long history in emerging-market restructuring) gives it a differentiated but narrow niche within that pool.

Scale within the cohort in FY2025 (approximate advisory revenue):

Sources: EVR_2026-07-10_full_report.md; HLI_2026-07-10_full_report.md; CT Acquisitions league-table replication; LAZ FY2025 10-K.

Lazard is a scaled top-10 global advisor by announced deal value (#8 in LSEG 2025 rankings), but it is no longer the largest public boutique. Evercore passed it decisively; Houlihan Lokey and Centerview are comparable or larger on advisory revenue. Lazard’s FY2025 advisory growth of +4–5% YoY materially trails Evercore’s +34%, implying share loss within the independent cohort even as the cohort gains share from bulge brackets.

3.2 M&A and restructuring cycle

Global M&A deal value was ~$4.5T in 2025 (up ~49% YoY), and 2026 is tracking toward ~$4.0T+, with megadeals (>$5B) now nearly half of total value. Private-equity deal value reached ~$2.2T globally in 2025 (+23% YoY), with U.S. PE deal value ~$1.16T (+31%). PE dry powder is widely cited at $1.3–2.6T. Lazard’s restructuring practice has been active on Altice France, GiFi, Global Clean Energy Holdings, Zachry Group, Bourbon, First Brands Group, Pine Gate Renewables, Superior Industries, Saks Global, SI Group, and Modivcare.

Sources: EVR FY2025 call; PwC mid-year outlook 2026; PitchBook/EONXI PE outlook; LAZ earnings releases; Zacks Q2 preview.

The cycle read: we are in an M&A upcycle, but mid-2026 is closer to mid-cycle than early innings. FY2025/Q1 2026 earnings sit near cyclical highs for the advisory sector, and management at Evercore and Lazard have warned against extrapolating blowout quarters. Mega-deals pulled forward closings into Q1 2026, making subsequent quarters harder comparisons. Private-equity exit activity, a key driver of sponsor advisory fees, remains sensitive to rate and policy uncertainty.

The countercyclical restructuring option is real — rate resets and maturity walls should eventually drive a pickup — but Lazard is tier-2 behind Houlihan Lokey, PJT, and Evercore in restructuring wallet share. Restructuring is also a lower-fee business per dollar of transaction value than M&A advisory; a surge in distressed mandates would help sentiment and fill capacity but would not fully offset a 20–30% correction in M&A fees.

3.3 Asset management industry headwinds

Lazard Asset Management is squarely in the structurally challenged middle of the asset-management barbell. Passive/ETF scale giants (BlackRock, Vanguard, State Street) and alternatives specialists (Blackstone, Apollo, KKR, Ares) are gaining share; traditional active public-market managers are in secular decline. The economics of scale in passive management are overwhelming: BlackRock can offer ETFs at 3–20 bps because distribution, technology, and brand amortize across trillions of dollars. At the other end, alternatives managers command 150–200 bps management fees plus 10–20% carried interest because their products are illiquid, capacity-constrained, and sold through relationships. Traditional active equity and fixed income sit in the squeezed middle, charging 50–100 bps while struggling to justify their fees against cheap passive options.

Active fee compression continues: average asset-weighted mutual fund fees fell to ~36 bps, ETF expense ratios to 3–20 bps, and active ETF fees to ~37 bps versus active mutual funds at ~132 bps. Only ~38% of active funds outperformed in 2025. Lazard’s FY2025 net outflows of $18.1B (even excluding one large sub-advised redemption) show it is still fighting the tide. The Elaia Partners acquisition and active-ETF/wealth push are sensible defensive moves, but they are small relative to the $254B+ base.

Sources: Morningstar 2025 trend reports; Citywire; AInvest fee-compression report; LAZ FY2025 release.

3.4 Talent war and competition

The advisory business is a talent war, not a capital war. LAZ’s 10-K explicitly states that competition is intense for “the attraction and retention of qualified employees” and that the firm competes on “the level and nature of compensation and long-term incentives.” Lazard’s adjusted compensation ratio was 65.5% in FY2025, in line with Evercore (~64–65%), Houlihan Lokey (~64%), and PJT (~67%). The elite-boutique share gain has been driven partly by the ability to pay senior MDs 30–50% above bulge-bracket levels at equivalent revenue generation.

Sources: LAZ 10-K FY2025 competition section; CT Acquisitions compensation analysis; peer FY2025 filings.

3.5 Regulatory landscape

Regulation is a cost of doing business, not a moat. LAZ’s U.S. broker-dealer is SEC/FINRA-registered and subject to net-capital Rule 15c3-1. The AM subsidiaries are SEC-registered investment advisers subject to the Investment Advisers Act of 1940 and ERISA/fiduciary obligations. Cross-border M&A faces CFIUS, DOJ/FTC antitrust, and EU/UK merger control. The real regulatory risks are deal-friction delays that push success-fee recognition into future quarters and conduct failures in asset management that can vaporize AUM faster than market moves.

Verdict: Financial advisory is a structurally mediocre-to-attractive industry with a critical caveat — capital-light, high-ROE, and benefiting from a secular share shift to independents, but with low barriers to entry, zero switching costs, and labor capturing ~60–65% of revenue. Asset management is structurally bad for Lazard’s positioning. The combined industry backdrop is mixed-to-unfavorable: Lazard sits in the challenged middle of both advisory and asset-management barbells.

4. Competitive Position

4.1 Moat taxonomy

Applying Greenwald’s framework, Lazard has no genuine durable advantage.

Supply-side / cost advantage: None. Advisory is labor-intensive; there are no scale economies in deal execution. A $50B M&A deal does not cost materially less per dollar of transaction value than a $5B deal; in fact, the largest deals often require more senior attention and external advisers. The “assets” (bankers) are expensed and walk out nightly. There is no machinery, patent, or network that lowers marginal cost as volume grows.

Demand-side / customer captivity: Very low. Clients hire deal-by-deal; there are no switching costs and no network effects. A CEO who used Lazard for one acquisition can just as easily use Evercore or Goldman Sachs for the next. The 10-K explicitly states there are “no long-term contracted sources of revenue” and “each revenue-generating engagement is separately negotiated and awarded.” Reputation reduces search costs but does not create captivity.

Scale + captivity: Weak. Scale shows up in brand and deal-flow, but Lazard is mid-sized among elite boutiques and has been losing relative share to Evercore and Centerview over the past decade. The brand is real for cross-border and sovereign advisory, and Lazard’s fairness-opinion credibility is valuable in conflict-driven mandates. But brand without captivity is a depreciating intangible. A rainmaker who leaves takes relationships with him; a client who leaves takes the next deal elsewhere. The only durable scale advantage in advisory is the platform’s ability to retain and recruit talent, which is precisely the dimension where Lazard has been struggling relative to faster-growing peers.

4.2 Comparison to Evercore and Houlihan Lokey

Sources: EVR and HLI private reports; LAZ FY2025 10-K; CT Acquisitions.

Evercore has built a larger, faster-growing platform with deeper capital-markets capabilities and a stronger bench below the named rainmakers. Its revenue per senior managing director is roughly double Lazard’s, indicating either superior productivity, higher-priced mandates, or both. Houlihan Lokey has the most cycle-hedged model, with restructuring and financial valuation as a counterweight to M&A cyclicality, plus a PE-funds business. Lazard’s differentiation — independence, cross-border heritage, sovereign advisory — is valuable but replicable and not translating into superior growth. The historic Lazard brand is a real asset, but brands in advisory do not compound the way they do in consumer products; they depreciate without constant reinforcement by live deal success and retained talent.

4.3 Marathon capital-cycle read

Returns look high in up-cycles (ROE ~37% in FY2021, ~22% in FY2022) but mean-revert sharply (ROE negative in FY2023). There is no physical capital cycle; the relevant cycle is talent. High returns attract boutique formation and lateral hiring, pinning compensation at ~60–65% of revenue. This is a people business whose returns are shared with labor.

Verdict: Lazard has a narrow, reputation-based intangible moat in large-cap/cross-border M&A and restructuring, but it is structurally weaker than Evercore’s scale-of-platform and far less diversified/cycle-hedged than Houlihan Lokey. The advisory business is best characterized as a high-quality people business with no real captivity.

5. Growth History and Forward Opportunities

5.1 Historical growth

Lazard’s revenue growth has been largely cyclical, not organic. Consolidated net revenue fell from $3.27B in FY2021 to $2.55B in FY2023 before recovering to $3.10B in FY2025. Financial Advisory revenue moved from $1.76B → $1.67B → $1.39B → $1.83B over the same period. Asset Management revenue declined from $1.43B in 2021 to $1.15B in 2023 and only recovered to $1.27B in 2025 — a new all-time high was never reached despite a strong equity market.

Headcount growth has been a partial driver: FA MDs rose from 179 at year-end 2021 to 216 at year-end 2025; AM MDs from 110 to 124. But revenue per MD fell from $10.5M in 2021 to $8.7M in 2025, indicating that headcount additions have not yet returned productivity to peak levels.

5.2 Lazard 2030 plan

CEO Peter Orszag introduced Lazard 2030 in September 2023. The goals:

• Double firmwide revenue from ~$2.5B in 2023 to ~$5B by 2030, implying ~10% CAGR.
• Average total shareholder return (TSR) of 10–15% per year through 2030.
• Growth split roughly evenly between Financial Advisory and Asset Management.
• Revenue per MD target of $12.5M by 2030, up from $8.9M in 2025 and $6.4M in 2023.
• Private-capital connectivity: from ~25% of advisory revenue historically to ~33% in 2023, ~40% for the 12 months ending June 2025, and a target of ~50%.

Sources: Lazard.com “Lazard 2030” letter dated 2025-09-10; Q1 2026 earnings call transcript.

A two-year progress update in September 2025 showed adjusted net revenue up 18% from FY2023 to FY2024, TSR up ~100% since October 2023, and MD net-add targets met/exceeded from Q1 2024 to Q1 2025. Strategic initiatives include proprietary AI tools, AI Champions, Perplexity CBO Dmitry Shevelenko added to the Board, wealth-management expansion in Europe/U.S./Middle East, active ETFs (Japan equity, equity megatrends, next-gen tech, international dynamic equity), and new offices in Denmark, Riyadh, and Abu Dhabi.

The credibility of the plan hinges on whether the 2023–2025 progress is self-help or cyclical rebound. Adjusted net revenue grew 18% from FY2023 to FY2024, but global completed M&A value rose ~24% in 2025 and announced value rose ~43%. Lazard’s advisory growth in FY2025 (+4–5%) materially lagged the market and peers, suggesting the firm is not gaining share in the recovery. The private-capital revenue mix shift from 25% to 40% is real, but much of the 40%→50% step will come from Campbell Lutyens (~$500M), not organic advisory growth. AI initiatives are sensible but replicable. The plan has more substance than pure rhetoric, but delivery remains cycle-dependent.

5.3 Campbell Lutyens acquisition

The Campbell Lutyens deal is the signature growth initiative. It combines Lazard’s existing private-capital advisory with Campbell Lutyens’ fund placement, secondaries, and GP capital advisory to create “Lazard CL.” Headline terms:

• $460M initial consideration + $115M deferred payment + up to $85M performance earn-out.
• All-stock headline at a $46.50 reference share price.
• Deferred/earn-out may be settled in stock, cash, and/or loan notes.
• Expected close: H2 2026.
• Target: ~$500M of combined 2027 revenue at mid-20s operating margins.

Sources: LAZ 8-Ks filed April 30 and May 1, 2026; Q1 2026 earnings call transcript (Tracy Farr quote on $46.50 reference price and all-stock nature).

If achieved, Campbell Lutyens alone could add ~$125M of operating income by 2027, or roughly $0.75–$0.90 of EPS after tax and noncontrolling interests. It would also move Lazard toward the 50% private-capital advisory revenue target.

5.4 Asset Management inflection?

Asset Management ended FY2025 with $254.3B of AUM, had net outflows of $18.1B for the full year, and then flipped to +$9.0B of net inflows in Q1 2026 — the first meaningful positive quarter in years. June 2026 AUM was $284.7B, including a $1.0B increase from acquiring a controlling interest in Elaia Partners. Management cautioned not to “straight line” the Q1 inflow. New AM CEO Chris Hogbin (ex-AllianceBernstein) was hired in late 2025/early 2026 to lead the turnaround.

Sources: LAZ FY2025 10-K; Q1 2026 10-Q; June 2026 AUM release; Q1 2026 transcript.

5.5 AI and productivity

Management has made AI a centerpiece of the 2030 productivity story. Orszag stated on the Q4 2025 call that the firm is “at the forefront” and that AI “is likely to lead us to be able to have a smaller team associated with each managing director.” AI tools are being customized in-house, and an AI Champion program is in place. However, quantified AI cost savings or implementation spend are not disclosed; management commentary is a hypothesis, not evidence.

Verdict: Growth quality is mixed. The 2030 plan has concrete metrics (MD additions, productivity target, private-capital revenue share) and the Campbell Lutyens acquisition gives it substance, but the revenue-doubling target requires ~10% annual growth that has not been achieved organically historically. Much of the 2023–2025 progress is cyclical rebound, not self-help. The Q1 2026 AM inflow is encouraging but not yet a trend.

6. Financial Quality

6.1 Consolidated income and profitability

Sources: LAZ 10-K FY2021–FY2025; Q1 2026 10-Q; ROIC.ai statements; source correction on FY2025 net revenue.

The cycle is vivid: peak margins and ROE in 2021, a 2023 loss driven by the M&A recession and restructuring charges, and a partial recovery that still leaves 2025 GAAP operating margin (12.0%) well below 2021 (24.4%). Adjusted operating income in 2025 was $432.2M versus GAAP operating income of $327.6M — a $104.6M gap (3.4% of net revenue). In 2023 the gap was $245.5M, turning an $80M GAAP operating loss into $165.6M of adjusted operating income.

6.2 Segment economics

*2022–2025 and Q1 2026 segment operating income is management’s adjusted segment operating income. 2021 figures are GAAP segment operating income from the 2022 10-K.

Advisory margins show genuine operating leverage — a 5% increase in adjusted net revenue in FY2025 drove an 11% increase in FA adjusted operating income — but the leverage is capped by the compensation ratio.

6.3 Compensation, headcount, and productivity

Sources: LAZ 10-K FY2023/FY2025; Q1 2026 10-Q; ROIC.ai per-share data.

Compensation is the real capital base. The adjusted comp ratio troughed around 58–60% in 2021–2022 and has stabilized around 65–66%. CFO Tracy Farr guided on the Q1 2026 call that the full-year comp ratio would be “similar to last year, around 65.5%,” contradicting earlier web-sourced language of a 60% target. This is a critical binding constraint: roughly two-thirds of incremental revenue flows to employees, so shareholder operating leverage is muted.

The implication for valuation is significant. If the adjusted comp ratio is structurally 65% and non-compensation expenses are 20% of revenue, the pre-tax margin ceiling is roughly 15% before interest, taxes, and noncontrolling interests. That ceiling is below FY2021 levels and explains why the 2025 adjusted operating margin of 14.3% is already close to a normalized upper bound. Margin expansion must come from non-compensation leverage (real estate, technology, support-staff efficiency), not from paying employees less. The Lazard 2030 productivity target ($12.5M revenue per MD) implicitly assumes revenue grows faster than headcount, but if incremental bankers require incremental support and the talent market remains competitive, the comp ratio will not compress.

6.4 Asset Management AUM and flows

Sources: LAZ 10-K FY2022–FY2025; Q1 2026 10-Q.

AUM has been essentially flat-to-down over five years ($273.7B at YE2021 → $254.3B at YE2025) because persistent net outflows offset market appreciation. The Q1 2026 +$9.0B inflow is the first meaningful positive quarter in years. The fee rate is low (~45–52 bps), reflecting a heavy mix of institutional index-aware/strategic-beta strategies and fixed income.

6.5 Balance sheet

At year-end 2025, Lazard held $1.47B of cash, $0.17B of short-term investments, $1.69B of senior notes, and $0.49B of operating-lease liabilities, for total debt of ~$2.17B and net debt of ~$219M. Net debt/EBITDA was 0.53x; total debt/EBITDA was 5.29x; EBITDA/interest expense was ~4.7x. Goodwill + intangibles were $395M; long-term investments $573M; operating-lease ROU assets $413M versus lease liabilities of $485M. Total stockholders’ equity was $989M; Lazard/common stockholders’ equity was $881M at Q1 2026.

Sources: LAZ 10-K FY2025 balance sheet and Note 13; Q1 2026 10-Q; ROIC.ai credit ratios.

Balance-sheet risk is modest. Advisory is asset-light, the senior notes are long-dated and fixed-rate, and net leverage is low. The real balance-sheet exposure is human capital (accrued compensation) and investment/seed-capital mark-to-market, not traditional financial leverage.

6.6 Free cash flow and earnings quality

Sources: LAZ 10-K FY2023/FY2025 cash-flow statements; Q1 2026 10-Q.

FCF conversion is healthy outside restructuring years. The 2025 payout ratio was ~38% of FCF, leaving dividend coverage adequate on a full-year basis. Q1 is structurally cash-negative due to bonus payouts; Q1 2026 operating cash flow was negative as accrued compensation declined by ~$580M seasonally.

Earnings quality is impaired by recurring “special” charges that blur the run-rate. Major items include: 2023 cost-saving initiative charges of $200M (severance, technology impairments, FX losses on office closings); 2024 $114M gain on sale of an owned office building plus $48.7M of additional cost-saving charges and $50M of senior-management-transition expense; 2025 $50M senior-management-transition expense, $26M noncontrolling-interest comp, and $24M LFI-related charges; Q1 2026 $78M gain on sale/deconsolidation of Edgewater management vehicles, $16.7M transition expense, and $2.4M Campbell Lutyens acquisition expenses. The effective tax rate has been volatile — 25.0% (2021), 24.1% (2022), benefit in 2023, 25.8% (2024), 23.4% (2025), and a negative rate in Q1 2026 despite pretax income — adding another layer of normalization complexity.

The gap between GAAP and adjusted operating income is material: $104.6M in FY2025 (3.4% of net revenue) and $245.5M in FY2023 (enough to turn an $80M GAAP operating loss into $165.6M of adjusted operating income). Some of these adjustments are genuine one-offs (building sale, Edgewater gain). Others — management transitions, LFI-related items, cost-saving initiatives — recur often enough that an investor normalizing earnings should haircut the run-rate rather than accept management’s adjusted figure at face value.

Verdict: Financial quality is mixed. The advisory franchise shows cyclical operating leverage, but 2025 margins remain far below 2021–2022 peaks. The compensation ratio is sticky around 65%, leaving limited margin cushion. Asset Management has bled assets for five consecutive years; the Q1 2026 inflow is encouraging but not yet a trend. Balance-sheet risk is low, FCF conversion is healthy, and earnings quality requires careful normalization.

7. Capital Allocation

7.1 Capital returns

Lazard returned $3.06B to shareholders via buybacks and dividends over FY2019–FY2025, split roughly 60% buybacks ($1.94B) and 40% dividends ($1.17B). Annual deployment was highly cyclical:

Sources: LAZ 10-K cash-flow statements; ROIC.ai per-share data.

The buyback program has been largely pro-cyclical: spending peaked in 2022 ($692M) when the stock was weak and advisory revenue was falling, then collapsed to $59–$102M in 2023–2025 even as the business recovered. The 2022 buybacks were likely value-accretive if the average price paid was near the 2022 lows, but the company did not sustain repurchases through the 2023 trough when the stock hit $23.73. Instead, buybacks remained anemic as the business recovered, and SBC-driven issuance has since reversed much of the 2021–2022 shrinkage. Net share count is now only modestly below 2019 levels despite $1.94B of gross buybacks.

The math is telling. In FY2025, gross buybacks were $91M while SBC amortization was ~$460M. The active repurchase authorization was $200M in July 2024, but only $109M remained at year-end 2025, implying the board is not treating buybacks as a high-priority use of capital. The 2018 Incentive Compensation Plan was amended in May 2024 to increase authorized shares by 20M, providing flexibility for Campbell Lutyens and future retention grants. Capital return has shifted from heavy buybacks to a stable dividend plus dilution-offsetting repurchases.

7.2 Dividend

Lazard has paid a regular quarterly dividend continuously. The quarterly dividend has been stable at $0.50/share since at least 2024 through the April 30, 2026 declaration, implying a $2.00 annualized run-rate (~4.6% yield at ~$43). The trailing-paid DPS was $1.91 in FY2025 (~4.4% yield). 2025 dividend coverage was ~38% of FCF but ~86% of GAAP EPS.

Sources: LAZ 10-K/10-Q dividend declarations; Q1 2026 10-Q Subsequent Events; ROIC.ai per-share data; source correction.

7.3 Strategic M&A and balance-sheet activity

The Campbell Lutyens acquisition is the first large strategic acquisition in recent years. It is structured as an all-stock headline transaction at a $46.50 reference share price, aligning sellers/employees and preserving balance-sheet optionality. Balance-sheet strategy has otherwise been prudent: the $500M 2025 notes were tendered in March 2024 and replaced with $400M 6.000% notes due 2031; the $300M 2027 notes were redeemed in 2025 and replaced with $300M 5.625% notes due 2035. Remaining maturities are $500M 4.50% due September 2028, $500M 4.375% due March 2029, $400M 6.00% due March 2031, and $300M 5.625% due August 2035. The $200M revolving credit facility expires June 2028.

Sources: LAZ 10-K FY2025 Note 13; 8-Ks filed March 2024, August 2025, April/May 2026.

7.4 Incentive alignment

CEO Peter Orszag’s 2025 awarded compensation was $15.0M ($0.9M salary, $3.9M cash bonus, $10.2M long-term incentives). 2026 target compensation is $16.0M with a maximum of $20.0M (125% cap). The 2026 firmwide scorecard governs 100% of CEO incentive pay and 50% of other NEO incentive pay; quantitative metrics are described as a “majority” of the scorecard and include adjusted net revenue, adjusted EPS, MD headcount, MD productivity, AM net flows, and average fee level. CEO long-term incentives are 50% TSR-PIPRs (3-year relative TSR vs. S&P 1500, payout range 0–150%) and 50% Performance Incentive Plan Restricted Stock Units. Ownership guidelines require CEO to hold equity equal to 6x base salary and other NEOs to hold 3x base salary.

Source: LAZ 2026 DEF 14A (filed April 7, 2026).

7.5 Insider activity

Insider activity over the trailing 24 months has been dominated by programmatic selling under Rule 10b5-1 plans and tax-withholding dispositions. No open-market purchases (Code P) were identified. Peter Orszag sold ~231K shares (~$10.4M) under 10b5-1 plans and disposed of ~138K shares (~$6.3M) under Code D, likely tax withholding. Kenneth Jacobs sold ~332K shares (~$16.2M) under 10b5-1 plans. Evan Russo sold ~200K shares (~$11.0M) under Code S. The flow is consistent with a transition-era management team monetizing equity compensation, not with discretionary panic selling — but there is no bullish accumulation signal either.

Source: SEC Form 4 review, July 2024–July 2026.

Grade: B. Strengths: a disciplined, stable dividend; low financial leverage; opportunistic debt refinancing that removed the 2025/2027 maturity wall; and a large 2022 buyback likely deployed at a low stock price. Weaknesses: buybacks have been inconsistent and heavily offset by SBC issuance; the Campbell Lutyens deal is a meaningful capital commitment with unproven returns; and insider open-market buying has been absent during the transition.

8. Changes and Headwinds — Last Two Years

8.1 Leadership reset

Lazard has undergone a full leadership reset under Peter Orszag:

• May 26, 2023: Peter Orszag appointed CEO, effective October 1, 2023; Kenneth Jacobs becomes Executive Chairman.
• January 2, 2024: Lazard completes re-domiciliation from Bermuda to Delaware as Lazard, Inc.
• November 25, 2024: Orszag appointed Chairman effective January 1, 2025; Jacobs becomes Senior Chairman.
• September 8, 2025: Evan Russo transitions out of Asset Management CEO role; Chris Hogbin joins as new AM CEO.
• February 2, 2026: Tracy Farr appointed CFO, replacing Mary Ann Betsch.
• July 7, 2026: Kathy Elsesser appointed to Board, succeeding Andrew Alper; board declassification approved by shareholders in May 2026.

Sources: LAZ 8-Ks filed 2023-05-26, 2024-01-02, 2024-11-25, 2025-09-08, 2026-02-02, 2026-05-22; Lazard press release July 7, 2026.

The reset is now complete (CEO, Chairman, CFO, AM CEO) and aligned with the Lazard 2030 operating plan. Governance is moving toward declassification and a more conventional U.S. public-company structure. These changes are likely net-positive but introduce execution risk from a newly assembled C-suite.

8.2 Strategic transactions

• Campbell Lutyens (April/May 2026): All-stock headline acquisition scaling private-capital advisory; expected ~$500M of 2027 revenue.
• Edgewater stake sale (Q1 2026): $78M gain on sale/deconsolidation of Edgewater management vehicles; non-core cash realization.
• 2024 owned-building sale: $114M gain on sale of an owned office building; part of the real-estate footprint shift from owned to leased facilities.

Sources: LAZ 8-Ks, 10-K, 10-Q.

8.3 Operating-model initiatives

• Lazard 2030: Revenue-doubling by 2030, $12.5M revenue per MD target, ~50% private-capital advisory revenue.
• AI integration: Customized proprietary AI tools, AI Champions, Perplexity CBO on the Board.
• Geographic expansion: New offices in Denmark, Riyadh, Abu Dhabi.
• Active ETFs / wealth: Launches in Japan equity, equity megatrends, next-gen tech, international dynamic equity; wealth expansion in Europe/U.S./Middle East.

Sources: Lazard 2030 letter; Q4 2025 and Q1 2026 earnings call transcripts.

8.4 Headwinds

• Advisory-cycle rollover risk: Management has warned against extrapolating strong quarters; Zacks preview expects Q2 2026 earnings to decline.
• Compensation-ratio stickiness: Full-year guidance ~65.5%, not the earlier 60% target.
• AM structural outflows: Five consecutive years of net outflows; Q1 2026 inflow is one data point.
• SBC dilution: Share count rising as equity issuance outpaces buybacks.
• Macro/geopolitical risk: High beta to financials/broker-dealer factor; tariff and geopolitical shocks drive large single-day moves.

Verdict: The changes under Orszag are directionally correct and material, but they are not yet a durable improvement in competitive position. The headwinds are cyclical (advisory) and structural (AM outflows, talent competition, SBC dilution).

9. Risk Analysis

Verdict: The risk matrix is skewed toward cyclical and people risks rather than balance-sheet fragility. The most consequential risks are an M&A downturn, AM outflow resumption, and Campbell Lutyens integration underperformance.

A few risks merit additional emphasis. First, the talent-flight risk is asymmetric: a single departing rainmaker does not move the needle, but a wave of departures to Evercore, Centerview, PJT, or newly formed boutiques would both reduce revenue and force Lazard to pay more to retain the remaining MDs. Second, the Campbell Lutyens deal is strategically sensible but execution-dependent; if key fund-placement professionals leave after the all-stock lock-up expires, the acquired revenue could dissipate. Third, the dividend, while covered by FCF, consumes ~86% of GAAP EPS; in a 2023-style trough, the board would face a choice between cutting the dividend and raising leverage. The balance sheet can absorb a temporary downturn, but the dividend floor is not absolute.

10. Valuation Discussion

10.1 Current multiples

At the July 17, 2026 close of $43.16:

Sources: LAZ Q1 2026 10-Q; ROIC.ai; AZI valuation data.

The P/B of ~5.2x uses diluted/common stockholders’ equity ($881.3M / 106.8M shares), which reconciles to AZI. The $15.28 BVPS figure from ROIC.ai does not reconcile to the filing and is not used.

10.2 Peer comparison

Sources: ROIC.ai valuation multiples; peer FY2025 reports.

Lazard trades at a 25–30% P/E discount to the pure boutiques, which is reasonable given slower advisory growth and a structurally weaker AM business. It trades in line with bulge brackets, suggesting the market prices its cyclicality similarly to a diversified bank rather than a premium boutique.

A P/AUM lens highlights the advisory premium embedded in the stock. Lazard’s market cap of ~$4.25B against AUM of $259B is 1.6% of AUM, higher than traditional active managers (Franklin Resources ~0.9%, Invesco ~0.8%) and even above BlackRock (~1.4%). That premium makes sense only if the advisory franchise is worth the majority of the enterprise value. If one values the AM segment at 1.0% of AUM (~$2.6B), the implied advisory stub is ~$1.6–2.0B, or roughly 0.9–1.1x advisory revenue. That is not expensive for a scaled advisory franchise in a good market, but it leaves little room for an advisory downturn.

10.3 Normalized earnings scenarios

*Net to common subtracts ~$13M noncontrolling interest in base/bear, ~$18M in bull. **FCF/share assumes FCF conversion of ~1.9x net income.

Sources: Segment revenue history from LAZ 10-K/10-Q; Campbell Lutyens economics from Q1 2026 transcript; historical FCF conversion.

The base-case EPS of ~$2.47 is consistent with the current TTM EPS of ~$2.60. The bear case ($1.12) is not far-fetched: advisory revenue already fell to $1,385M in FY2023, and a 10% adjusted operating margin is roughly where the business troughed. The bull case requires advisory revenue to exceed the FY2021 peak plus a meaningful Campbell Lutyens contribution.

10.4 Embedded expectations

At ~$43, the market is underwriting a “muddle through” mid-cycle outcome: advisory revenue near $1.75B (versus $1.83B in FY2025), adjusted operating margin around 14–15%, stable AM revenue of $1.25–1.30B, modest Campbell Lutyens contribution, and a safe 4.6% dividend. The multiple is neither trough-cheap nor peak-expensive. It is consistent with the 2025 average P/E of ~20x and well above the 2021–2022 trough multiples of 8–9x.

The key asymmetry: the bull case (Campbell Lutyens + restructuring + AM inflection) is not fully priced, while the bear case (advisory downturn + margin compression) is partially priced via the discount to boutiques but not fully. The most fragile load-bearing assumption for the bull is that advisory revenue/margins do not roll over before Campbell Lutyens can offset them. The most fragile load-bearing assumption for the bear is that the Q1 2026 AM inflows and Campbell Lutyens integration fail, exposing the stock to a 2023-style margin reset.

Own-history context reinforces the mid-cycle read. In FY2021, diluted EPS was $4.65 and the year-end price was $43.63, implying a 9.4x P/E. Today, with EPS at roughly half that level, the P/E is 16.6x. The market has re-rated the multiple as earnings recovered, paying for turnaround rather than peak. In the FY2023 trough, the year-end price was $34.80 and P/B was ~2.2x on then-diluted book; today’s P/B is ~5.2x. The recovery has already been priced into the multiple.

Verdict: Lazard is fairly priced for a mid-cycle outcome and offers optionality if bull assumptions materialize. P/B ~5.2x removes any deep-value margin of safety. The stock is a cyclical/advisory recovery bet whose timing depends on the capital-markets cycle, not a high-conviction compounder.

11. Variant Perception

11.1 Consensus belief

The consensus view, reflected in the ~16.6x trailing P/E and the discount to pure boutiques, is that Lazard is a cyclical advisory franchise with a turnaround story under Peter Orszag, but with less growth and less moat than Evercore or Houlihan Lokey. The market is giving partial credit to Lazard 2030 and Campbell Lutyens while pricing in continued AM headwinds and advisory-cycle risk. The dividend yield provides a floor.

11.2 Bull case

• Campbell Lutyens delivers $500M of 2027 revenue at 25% operating margins, adding ~$0.75–$0.90 EPS.
• A restructuring upswing driven by rate resets and maturity walls offsets any M&A slowdown.
• AM inflows sustain after five years of outflows, stabilizing fee revenue and improving sentiment.
• AI-driven productivity gains allow revenue per MD to approach the $12.5M target without proportional compensation inflation.
• Relative value vs. boutiques closes as LAZ’s P/E re-rates toward EVR/HLI.

11.3 Bear case

• The M&A cycle rolls over in H2 2026, pushing advisory revenue back toward the $1.4B trough.
• The adjusted comp ratio stays stuck above 65%, preventing margin expansion and leaving no cushion if revenue falls.
• AM outflows resume, confirming structural decline and pressuring fee rate further.
• Campbell Lutyens integration disappoints, with revenue synergies below target and key professionals leaving.
• SBC issuance continues to dilute shareholders, neutralizing buybacks and capping EPS growth.

11.4 Key assumptions and factor positioning

Factor positioning: LAZ is a high-beta dividend/financial/broker-dealer bundle. The All Factors model R² is 61.1%, with significant loadings on Market (+1.42), DividendYield (+0.82), a Wall Street Giants custom factor (+0.65), SmallSize (+0.51), Financials sector (+0.39), and Broker-Dealer industry (+0.30). Momentum, Value, Quality, and Growth style factors are absent (zeroed by the ElasticNet model), meaning LAZ does not currently present a clean style tilt.

The 1-year factor regime has been hurtful to LAZ’s financial/broker-dealer exposure (z ≈ -1.6 to -2.0) but helpful to its dividend-yield exposure (z ≈ +1.66). Short-term, financials and value are bouncing (positive z), while low-volatility is working strongly (z = +1.76) — a headwind because LAZ is negatively loaded to LowVol. The positioning read is therefore mixed-to-slightly-negative: the stock is unlikely to outperform until capital-markets optimism or value/financials leadership returns. The 39% idiosyncratic variance means company-specific developments (Campbell Lutyens, AM flows, earnings surprises) can matter, but the factor tide is not running in LAZ’s favor.

12. Fact vs. Interpretation

13. Open Questions

1. Is the Q1 2026 +$9B AM inflow an inflection point or a one-off mandate win? Management explicitly cautioned against straight-lining it.
2. What is the updated compensation-ratio guidance for FY2026 and 2030? CFO Farr guided ~65.5% for FY2026, but the earlier 60% target has not been formally walked back.
3. How much of Campbell Lutyens’ $500M 2027 revenue target is already in run-rate backlog versus new business?
4. What are the integration milestones, retention arrangements, and revenue-synergy evidence for Campbell Lutyens?
5. Will AI-driven productivity gains materialize in measurable cost savings, or are they mostly incremental research quality?
6. Is the current M&A cycle mid-cycle or late-cycle? This is the single biggest driver of whether embedded advisory assumptions are too high or too low.
7. What is the precise impact of the February 2026 Edgewater deconsolidation on future AM fee streams and AUM?
8. Why does ROIC.ai report YE2025 BVPS of $15.28 when the filing-based diluted/common BVPS is $8.25?

14. What Must Be True

14.1 Bull case

1. Advisory revenue does not roll over before Campbell Lutyens closes and contributes.
2. The adjusted compensation ratio does not rise above 65–66% even as revenue grows.
3. Asset Management posts sustained positive net flows (>$3–5B/quarter) under Chris Hogbin.
4. Campbell Lutyens delivers at least $400M of revenue at 20%+ operating margins by 2027.
5. Macro/factor regime shifts back toward financials/value and away from low-volatility/defensive.

Falsification test: Two consecutive quarters of advisory revenue declining >10% YoY, or Q2/Q3 2026 AM net outflows, would break the bull thesis.

14.2 Bear case

1. The M&A cycle peaks in H1 2026 and advisory revenue corrects 20%+ from FY2025.
2. The compensation ratio stays sticky around 65.5%, leaving no margin cushion.
3. AM outflows resume as active-manager structural decline continues.
4. Campbell Lutyens integration disappoints or the deal is delayed/dilutive.
5. SBC issuance continues to outpace buybacks, capping EPS growth even if revenue stabilizes.

Falsification test: Advisory revenue re-accelerates above +10% YoY for two quarters, or AM inflows sustain above $5B/quarter, would break the bear thesis.

15. Source Appendix

Primary sources used in this memo are public filings, transcripts, and third-party data. Key primary sources:

• SEC filings: LAZ 10-K FY2021–FY2025, 10-Q Q1 2026, DEF 14A 2026, and 8-Ks filed 2023–2026 (SEC EDGAR).
• Earnings call transcripts: Q4 2025, Q1 2026
• Company documents: Lazard.com “Lazard 2030” letter dated 2025-09-10.
• Data providers: ROIC.ai (financial statements, ratios, valuation multiples, stock price); AZI (price history, valuation_index); FactorsToday (factor loadings and regime data).
• Industry/peer context: Prior reports on Evercore (EVR) and Houlihan Lokey (HLI); CT Acquisitions league-table replication; PwC, PitchBook/EONXI, MUFG, Morningstar, AInvest, Citywire, IPE, Reuters, Harvard Law School Forum on Corporate Governance.

All sources below are public.

APPENDIX A — Standard Diligence Questionnaire

Lazard Inc (NYSE: LAZ) — Report date 2026-07-19

Date: 2026-07-19

This appendix answers the standard diligence questionnaire for Lazard Inc, applying investment-bank / asset-manager analogs where the standard manufacturing-industry framing does not map. All figures reflect the evidence-based corrections: FY2025 net revenue is $3,098.8M; Campbell Lutyens is an all-stock transaction at a $46.50/share reference price; the quarterly dividend is $0.50/share ($2.00 annualized).

General — What thoughtful questions have other investors asked?

Is the advisory cycle at trough, mid-cycle, or near peak?

• FACT: Global M&A deal value was ~$4.5T in 2025 (+49% YoY) and 2026 is tracking toward ~$4.0T+; megadeals (>$10B) hit a record 70 in 2025. LAZ’s Financial Advisory revenue troughed at $1,385M in FY2023, rebounded to $1,834M in FY2025, and Q1 2026 was $360M (seasonally weak, -2% YoY). (SEC 10-K)
• INTERPRETATION: The cycle is closer to mid-cycle than trough. FY2023 was the trough; FY2024–25 was the rebound. Management and peers have warned against extrapolating strong quarters, and Q1/Q2 2026 commentary points to pulled-forward closings and slower sequential momentum.

What is normalized EPS / earnings power?

• FACT: FY2025 diluted EPS was $2.23; TTM diluted EPS is ~$2.60. Scenario work estimates base-case (mid-cycle) EPS of ~$2.40–$2.50, bear (trough) EPS of ~$1.12, and bull (peak + Campbell Lutyens) EPS of ~$3.60. (10-K/10-Q)
• INTERPRETATION: Current TTM EPS of ~$2.60 sits near mid-cycle earnings power. The market is not pricing a trough, nor is it fully underwriting the bull case.

Is LAZ gaining or losing share versus Evercore / Houlihan Lokey?

• FACT: Evercore’s FY2025 advisory revenue grew ~+34% YoY to ~$3.27B; Houlihan Lokey advisory revenue was ~$2.39B; LAZ Financial Advisory grew only +4–5% YoY to $1.83B. Lazard ranks #8 globally by announced M&A value; Evercore ranks #6. (peer 10-Ks; CT Acquisitions league tables)
• INTERPRETATION: LAZ is losing relative share within the elite independent advisory cohort. The boutique category is gaining share from bulge brackets, but Lazard is not capturing that shift as fast as Evercore or Centerview.

Is Lazard 2030 credible?

• FACT: Lazard 2030 targets doubling 2023 revenue (~$2.5B) to ~$5B by 2030 (~10% CAGR), 10–15% annual TSR, 10–15 net MD additions per year, $12.5M revenue per MD by 2030, and private-capital connectivity rising to ~50% of advisory revenue. The Campbell Lutyens acquisition is expected to contribute ~$500M of 2027 revenue at mid-20s operating margins. (Lazard 2030 letter; Q1 2026 transcript)
• INTERPRETATION: The plan is credible but cycle-dependent. The concrete metrics give it substance, but FY2024–25 progress was partly a cyclical rebound, not purely self-help. Much of the private-capital step-up will come from Campbell Lutyens rather than organic advisory growth.

What is Campbell Lutyens worth?

• FACT: Campbell Lutyens was agreed at $460M initial consideration + $115M deferred + up to $85M earn-out (max $660M), referenced to LAZ shares at $46.50. Management targets ~$500M of combined 2027 revenue at mid-20s operating margins. (8-Ks filed Apr 30 / May 1, 2026; Q1 2026 transcript)
• INTERPRETATION: At a 25% margin, Campbell Lutyens could add ~$125M operating income, or roughly $0.75–$0.90 EPS after tax if integration succeeds. ASSUMPTION: The $500M target is aspirational; actual FY2027 delivery depends on closing timing, retention, and market conditions.

Cyclicality & Earnings Nature

Where in the M&A / restructuring cycle is the business?

• FACT: LAZ’s Financial Advisory revenue fell from $1,764M in FY2021 to $1,385M in FY2023 (-21%), then rebounded to $1,834M in FY2025 (+32% from trough). Global M&A value troughed in 2023 and rebounded sharply in 2024–25.
• INTERPRETATION: Earnings are mid-cycle, not trough. The restructuring pipeline should rise with rate resets and maturity walls, but LAZ is tier-2 behind PJT/Houlihan Lokey in restructuring market share.

Are earnings driven by the external environment or management actions?

• FACT: Advisory revenue correlates with global M&A volume, PE activity, and capital-markets sentiment. Asset Management revenue depends on AUM levels, market appreciation, and net flows. Management actions (cost cuts, MD hiring, AI, Campbell Lutyens) matter at the margin.
• INTERPRETATION: Earnings are primarily externally driven. The M&A cycle and equity-market beta explain most of the revenue variance. Management actions can shift share and margins modestly but cannot override a frozen deal market.

How stable are revenues?

• FACT: Top 10 clients were ~17% of Financial Advisory net revenue in FY2025; no single client >10%. Each engagement is separately negotiated; there are no long-term contracted revenue streams. (10-K Item 1)
• INTERPRETATION: Revenues are episodic and success-fee driven. Asset Management management fees are more stable (~$1.2B annually), but advisory fees can swing ±30% year-over-year.

Market size and growth of advisory and asset management.

• FACT: Global M&A advisory fees are a ~$100B+ annual revenue pool tied to ~$4T+ of deal value. Traditional active asset management is structurally challenged by passive migration; active equity fund fees continue to compress (~36 bps asset-weighted). (Morningstar)
• INTERPRETATION: Advisory is a growing-but-cyclical profit pool for independents; AM is a shrinking-share pool for traditional active managers. LAZ sits in the middle of both.

Business Quality & Competitive Moat

Is the industry getting more or less competitive?

• FACT: Elite boutiques gained >27% of US M&A advisory fees by 2024 vs. <15% in 2018. LAZ’s FY2025 advisory growth (+4–5%) materially trails Evercore (+34%). LAZ hired Brian McCabe from JPMorgan in May 2026 to head North American energy investment banking. (Reuters)
• INTERPRETATION: Competition is intensifying. The boutique category is winning from bulge brackets, but within the category LAZ is not keeping pace. Talent wars and boutique formation are rising.

Profitability — ROIC, ROE.

• FACT: LAZ ROE peaked at 37.0% in FY2021, was negative in FY2023 (-4.9%), and recovered to 16.0% in FY2025. Adjusted Financial Advisory operating margin was 24.2% in FY2025; Asset Management was 23.1%. (Financials Tables; 10-K)
• INTERPRETATION: Profitability is high in up-cycles, mean-reverting in downturns. This is characteristic of asset-light advisory franchises. There is no durable 20%+ through-cycle ROE.

Barriers to entry.

• FACT: LAZ has 216 Financial Advisory MDs, a global footprint, and a 176-year brand. The 10-K states there are no long-term contracts and competition is intense for clients and employees. (10-K)
• INTERPRETATION: Barriers are moderate at the platform level, low at the single-MD level. A rainmaker can leave and start a boutique; a scaled brand and global fairness-opinion credibility take years to replicate.

Can the business be undermined by foreign low-cost labor?

• FACT: Advisory is a senior-relationship, judgment, and negotiation business. Offshoring of execution support exists, but client-facing M&A advice is not commoditizable.
• INTERPRETATION: Foreign low-cost labor is not a material threat. This is a high-touch, reputation-driven people business, not a manufacturing or IT-services model.

Do brands matter? What are switching costs?

• FACT: LAZ’s brand matters for cross-border M&A, sovereign advisory, and special-committee assignments. Clients hire deal-by-deal; top 10 clients are ~17% of FA revenue.
• INTERPRETATION: Brand matters, but switching costs are near-zero. Relationships are personal and portable. The moat is narrow and reputation-based, not contractual.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet.

• FACT: Goodwill + intangibles were $395M at YE2025. The firm’s true intangible assets are its brand, MD relationships, and fairness-opinion credibility; these are expensed, not capitalized. (10-K)
• INTERPRETATION: The most valuable assets (human capital / reputation) do not appear on the balance sheet. Reported goodwill is modest and primarily reflects historical acquisitions.

Off-balance-sheet liabilities.

• FACT: Operating lease liabilities were $485M at YE2025 (undiscounted payments ~$578M). Long-term investments were $573M, including $285M related to LFI / deferred-comp arrangements. Campbell Lutyens earn-out: up to $85M contingent on revenue growth through 2030. (10-K)
• INTERPRETATION: Off-balance-sheet exposure is modest. The lease obligation is the largest item. The Campbell Lutyens earn-out and unfunded LP/co-investment commitments are not fully quantified.

How conservative is the accounting?

• FACT: FY2025 adjusted operating income was $432M vs. GAAP operating income of $328M — a $105M gap (3.3% of revenue). In FY2023 the gap was $246M, turning an $80M GAAP operating loss into $166M adjusted operating income. Management adds back transition, real-estate, and LFI-related items.
• INTERPRETATION: Accounting is standard for the sector but requires careful adjustment. The GAAP/adjusted gap is material and recurring, not one-time. Investors should treat adjusted figures as the operating baseline but scrutinize add-backs.

How CapEx-hungry is the business?

• FACT: Capex was $32M in FY2025, $46M in FY2024, and $28M in FY2023 — consistently <2% of revenue. (10-K cash-flow statements)
• INTERPRETATION: CapEx intensity is minimal. The real capital base is human capital (compensation), not physical plant. The correct analog is R&D / talent investment, not industrial capex.

Capital Allocation & Management

How much FCF does the business generate, and how is it used?

• FACT: FY2021–25 cumulative FCF was ~$2.93B. FY2025 FCF was $487M; TTM FCF was ~$266M (depressed by Q1 seasonal working-capital outflow). Capital returned over FY2019–25 was ~$3.06B (~60% buybacks, ~40% dividends).
• INTERPRETATION: FCF generation is healthy outside restructuring years. The firm returns most FCF to shareholders, with buybacks that have been highly cyclical.

Significant acquisitions recently?

• FACT: Campbell Lutyens ($460M initial + $115M deferred + up to $85M earn-out, all-stock at $46.50/share reference) announced April 2026, expected close H2 2026. The “Verger acquisition” referenced in the research brief could not be verified in the SEC corpus.
• INTERPRETATION: Campbell Lutyens is the defining strategic move of the Orszag era, scaling private-capital advisory. It is materially larger than LAZ’s typical tuck-in history.

Buying back shares?

• FACT: Buybacks peaked at $692M in FY2022 (when the stock was weak), then fell to $59–$102M annually in FY2023–25. Share count fell from 100.7M at YE2021 to 86.0M at YE2022, then rose to 93.9M at YE2025 and 99.5M at Q1 2026 due to SBC issuance. (10-K/10-Q)
• INTERPRETATION: Buybacks have been pro-cyclical and largely offset by dilution. The 2022 repurchase was well-timed, but net shrinkage has been modest relative to gross spending.

Issuing large amounts of new shares to insiders?

• FACT: Shares outstanding rose from 86.0M at YE2022 to 99.5M at Q1 2026 — a 15.7% increase. 2025 gross buybacks ($91M) were only ~20% of annual SBC amortization (~$460M). The 2018 Incentive Plan was amended in May 2024 to add 20M authorized shares.
• INTERPRETATION: SBC-driven dilution is a meaningful offset to capital return. The Campbell Lutyens all-stock deal will add further share issuance.

Dividend policy.

• FACT: Quarterly dividend has been $0.50/share since at least 2024 through the April 30, 2026 declaration, implying $2.00 annualized. Trailing-paid DPS was $1.91 in FY2025.
• INTERPRETATION: The dividend is stable and well covered by normalized FCF (~38% payout of FY2025 FCF), but consumes a high share of GAAP EPS.

Compensation policy of directors / management.

• FACT: CEO Peter Orszag 2025 awarded compensation was $15.0M ($0.9M salary, $3.9M cash bonus, $10.2M LTI). 2026 target is $16.0M with a $20.0M max. The firmwide scorecard governs 100% of CEO incentive and 50% of other NEOs’ incentive. CEO LTI is 50% TSR-PIPRs (3-year relative TSR vs. S&P 1500) and 50% performance-based PIPRs. Ownership guidelines: CEO 6x base salary; other NEOs 3x.
• INTERPRETATION: Compensation design is broadly aligned with shareholders — equity-heavy, relative-TSR-linked, with ownership guidelines. The 125% payout cap limits upside leverage.

Motivations of management / insider behavior.

• FACT: No open-market insider purchases were identified in the trailing 24 months. Peter Orszag, Kenneth Jacobs, and Evan Russo sold shares under Rule 10b5-1 plans; Orszag also had tax-withholding dispositions on vesting.
• INTERPRETATION: Selling has been programmatic, not panic-driven, but there is no bullish accumulation signal. Management is focused on executing the Orszag turnaround / Lazard 2030 plan.

Valuation & Market Data

Is the stock an ADR, MLP, or K-1 issuer?

• FACT: LAZ is a US domestic issuer (Delaware corporation, formerly Bermuda-domiciled Lazard Ltd). It is not an ADR, MLP, or K-1 issuer. (SEC filings; 8-K Jan 2, 2024)

Dividend policy.

• FACT: Quarterly dividend is $0.50/share ($2.00 annualized). At ~$43/share reference price, the annualized yield is ~4.6%.

How profitable is the business?

• FACT: FY2025 GAAP operating margin was 12.0%; adjusted operating margin was ~14.3%. ROE was 16.0% in FY2025 vs. 37.0% in FY2021. TTM diluted EPS is ~$2.60. (Financials Tables)
• INTERPRETATION: Profitability is cyclically decent but below prior peak. The business is not structurally broken, but margin recovery has stalled relative to FY2021–22.

Is net income diverging from cash from operations?

• FACT: FY2025 net income was $237M; operating cash flow was $519M. Historical FCF conversion is ~2.0x net income outside restructuring years. Q1 is structurally cash-negative due to bonus payouts.
• INTERPRETATION: OCF/NI divergence is normal for this model. Working capital (accrued compensation) and non-cash SBC create a gap. Cash conversion is healthy once restructuring charges and seasonal payouts are normalized.

Risks & Downside

What factors would cause the stock to decline?

• FACT/INTERPRETATION:

1. M&A freeze — advisory revenue fell 21% from FY2021 to FY2023; a repeat would cut earnings sharply.
2. Asset Management outflows — five consecutive years of net outflows (FY2021–25) despite rising markets; Q1 2026 +$9B inflow is one quarter.
3. Talent flight — MDs are the productive assets; lateral losses to Evercore/Centerview/PJT would hurt revenue and morale.
4. Campbell Lutyens integration failure — $660M maximum consideration for a people business with earn-out risk.
5. SBC dilution — share count has expanded 15.7% from YE2022 to Q1 2026.

Risk of catastrophic / total loss?

• FACT: LAZ is asset-light with $1.47B cash, modest net debt (~$219M at YE2025), and no near-term debt maturities. There are no convertible notes or complex financing vehicles.
• INTERPRETATION: Total-loss risk is low. The equity can re-rate sharply lower in a downturn, but there is no balance-sheet insolvency risk akin to a levered bank or MLP.

Drawdown profile.

• FACT: 5-year low was $23.73 on 2023-11-13; 5-year high was $56.90 on 2024-11-06. Current price ~$43 is -24% from the high and +82% from the low. (AZI price CSV)
• INTERPRETATION: The stock is high-beta (~1.6) and cyclical, capable of 40–60% drawdowns around cycle turns.

Recent News & Events — Has the business environment changed?

Two-year change timeline (2024–2026).

• INTERPRETATION: The last two years have been a full strategic, leadership, and governance reset under Orszag. The business environment has shifted from defense (cost cuts, restructuring charges) to offense (Campbell Lutyens, MD hiring, private-capital build-out). The key question is whether the offensive moves can outrun the next advisory-cycle downturn.

Summary Diligence View

Lazard is a capital-light, cyclical advisory franchise with a structurally challenged asset-management stub. The advisory business is mid-cycle, with genuine operating leverage but a 65%+ compensation ratio that captures most incremental economics. The moat is narrow and reputation-based; LAZ is losing relative share to faster-growing boutiques. Capital allocation is disciplined on dividends and balance-sheet leverage but inconsistent on buybacks, with SBC dilution offsetting much of the 2021–2022 shrinkage. The Campbell Lutyens acquisition is the central strategic bet and the largest near-term swing factor. Total-loss risk is low, but the equity is high-beta and vulnerable to an M&A downturn or AM outflow resumption.

No BUY/SELL recommendation or price target is included in this appendix.

APPENDIX B — Source Appendix

Lazard Inc (NYSE: LAZ) — Report date 2026-07-19

Public source appendix | 2026-07-19

This appendix inventories the primary and secondary public sources used in this research. All citations below are drawn from SEC EDGAR filings, public earnings-call transcripts, public data feeds, and trade press.

(a) SEC filings — primary source corpus

Annual Reports on Form 10-K

Key 10-K items referenced:

• Consolidated Statements of Operations (net revenue, operating income, EPS)
• Consolidated Statements of Cash Flows (OCF, capex, buybacks, dividends)
• Consolidated Balance Sheets (cash, debt, equity, AUM-related investments)
• Note 18 — Adjusted net revenue, adjusted compensation, adjusted operating income reconciliation
• Note 23 — Segment Information (FA / AM revenue and operating income)
• Note 13 — Senior Debt table
• Lease footnote — ROU assets and operating-lease liabilities
• Restructuring / cost-saving initiative note ($200M charge in 2023, $48.7M in 2024)
• Gain on sale of owned office building ($114.3M in 2024)

Quarterly Reports on Form 10-Q

Key Q1 2026 10-Q items referenced:

• Consolidated net revenue $756.6M; diluted EPS $0.91
• Segment revenue and adjusted operating income
• AUM roll-forward: ending AUM $259.2B; net inflows +$9.0B
• Balance sheet: Lazard/common stockholders’ equity $881.3M; diluted shares 106.8M
• Note 21 — Gain on sale / deconsolidation of Edgewater management vehicles ($78.0M)
• Campbell Lutyens acquisition note ($2.4M acquisition expenses)

Current Reports on Form 8-K (selected)

All 51 Form 8-K filings from 2019–2026 were reviewed; selected items are listed above.

Proxy Statements (DEF 14A)

Key proxy items referenced:

• 2025 NEO awarded compensation (Orszag $15.0M total: $0.9M salary, $3.9M cash bonus, $10.2M LTI)
• 2026 incentive design: firmwide scorecard, 125% payout cap, CEO LTI 50% TSR-PIPRs / 50% PIPRs
• Board declassification proposal (approved May 21, 2026)
• Ownership guidelines, anti-hedging/pledging policies, clawback provisions

Other SEC filings

• Annual Reports to Shareholders (ARS), S-3ASR shelf registrations, S-4, S-8, POS AM, PRE 14A, DEFA14A — available via SEC EDGAR search for LAZ.
• Form 4 insider transactions — available via SEC EDGAR insider filings.

(b) Earnings call transcripts

Key transcript-sourced claims:

• Campbell Lutyens all-stock consideration, $46.50 reference share price, $500M anticipated 2027 revenue, mid-20s operating margins (Q1 2026)
• CFO Tracy Farr full-year comp-ratio guidance ~65.5% (Q1 2026)
• Asset Management net inflows $9B, average management fee 44.6 bps (Q1 2026)
• Lazard 2030 productivity target $12.5M revenue per MD (Q4 2025)

© Data feeds and price/factor data

(d) News / trade press / company announcements

(e) Regulatory / public references

• SEC / FINRA net-capital Rule 15c3-1 disclosure in 10-K Item 1
• Investment Advisers Act of 1940, Investment Company Act of 1940, ERISA/fiduciary obligations (10-K)
• CFIUS, DOJ/FTC, EU/UK merger-control references (10-K risk factors)
• FCPA, OFAC, anti-bribery/AML/sanctions compliance (10-K)

(g) Claims not directly primary-sourced

The following claims or estimates in the consolidated working notes are not directly verifiable from SEC filings or company transcripts and should be treated as secondary / directional:

1. Lazard 2030 revenue-doubling target ($2.5B → $5B by 2030, ~10% CAGR). Primary source is the Lazard.com 2030 letter (2025-09-10), which was referenced but not downloaded locally. The original web-search summaries of the letter were used.
2. $12.5M revenue-per-MD target by 2030. Orszag confirmed this target on the Q4 2025 call, so it is transcript-sourced; however, the original source was a third-party AInvest news summary.
3. Global M&A value (~$4.5T in 2025, +49% YoY; mega-deal counts). Sourced from Evercore management commentary, Dealogic/LSEG, PwC, CT Acquisitions, and MUFG — third-party league-table and consulting data.
4. Lazard restructuring market-share ranking (#3 globally, 50 deals in 2025). Sourced from CheckThat.ai / third-party league tables; Lazard does not disclose restructuring revenue separately.
5. Advisory peer revenue scale (Evercore ~$3.27B, Houlihan Lokey ~$2.39B, Centerview ~$2.1B, PJT ~$1.5B, Moelis ~$1.5B). Derived from peer filings and trade-league-table summaries; exact fiscal-year timing and GAAP/adjusted basis vary.
6. Brian McCabe hire as head of North American energy investment banking. Sourced to Reuters/World Energy News “people familiar”; no formal Lazard press release was located.
7. Venezuela sovereign-debt mandate story. Mentioned in ROIC.ai news sweep; not independently verified.
8. ROIC.ai book value per share $15.28 for YE2025. Does not reconcile to the 10-Q filing ($8.25 diluted/common BVPS). This data item should be treated as erroneous and retired.
9. FY2025 net revenue $3,148.0M in Financials Tables. Does not reconcile to the 10-K ($3,098.8M). Correction flagged in evidence verification entry.
10. Campbell Lutyens “all-stock” framing. The 8-Ks describe the dollar consideration but do not specify the form. The all-stock nature and $46.50 reference price come from the Q1 2026 earnings call transcript (Tracy Farr), which is a primary management source but not a filed SEC document.

End of source appendix.